Position in AZN
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$928,332,681
+$197,539,495 QoQ
Shares Held
4,895,753
+32.1% QoQ
Ownership
0.316%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
#42
of 1,459 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AZN Over Time
Shares Held
Position Value (USD)
Derivatives in AZN
reported options exposure · as of Jun 30, 2026CallValue
$14,335,272
CallShares
75,600
PutValue
$29,391,100
PutShares
155,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CITIGROUP INC holds $6,106,168,968 across 18 Drug Manufacturers - General names. AZN ranks #3 (15.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,199,053 | $1,438,180,257 | |
| 2 | JNJ |
Johnson & Johnson
|
3,925,186 | $996,879,486 | |
| 3 | AZN |
Astrazeneca PLC
This page
|
4,895,753 | $928,332,681 | |
| 4 | ABBV |
AbbVie Inc.
|
2,327,207 | $585,618,368 | |
| 5 | MRK |
Merck & Co., Inc.
|
3,614,905 | $464,515,291 | |
| 6 | PFE |
Pfizer Inc
|
19,228,115 | $463,013,007 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
2,969,159 | $375,123,546 | |
| 8 | AMGN |
Amgen Inc
|
1,020,869 | $369,677,081 |
All Filings in AZN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $29,391,100 | 155,000 | Put | Defined | 2026-08-03 | |
| 2026-06-30 | $14,335,272 | 75,600 | Call | Defined | 2026-08-03 | |
| 2026-06-30 | $928,332,681 | 4,895,753 | Shares | Defined | 2026-08-03 | |
| 2026-03-31 | $730,793,186 | 3,705,472 | Shares | Defined | 2026-05-11 | |
| 2026-03-31 | $39,444,000 | 200,000 | Put | Defined | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||